Cargando…

Resonant laser ionization and mass separation of (225)Ac

Mostrar otras versiones (1)

[Formula: see text] Ac is a radio-isotope that can be linked to biological vector molecules to treat certain distributed cancers using targeted alpha therapy. However, developing [Formula: see text] Ac-labelled radiopharmaceuticals remains a challenge due to the supply shortage of pure [Formula: see...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Jake D., Heines, Michael, Bruchertseifer, Frank, Chevallay, Eric, Cocolios, Thomas E., Dockx, Kristof, Duchemin, Charlotte, Heinitz, Stephan, Heinke, Reinhard, Hurier, Sophie, Lambert, Laura, Leenders, Benji, Skliarova, Hanna, Stora, Thierry, Wojtaczka, Wiktoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873802/ https://www.ncbi.nlm.nih.gov/pubmed/36693865 http://dx.doi.org/10.1038/s41598-023-28299-4

Ejemplares similares

Resonant laser ionization and mass separation of $^{225}$Ac
por: Johnson, Jake D, et al.
Publicado: (2023)

Radium and Francium beam tests to produce 225Ac/ 213Bi generators at CERN-MEDICIS
por: Bruchertseifer, Frank, et al.
Publicado: (2015)

Towards reliable production of 225Ac for medical applications: Systematic analysis of the production of Fr, Ra and Ac beams.
por: Dockx, Kristof, et al.
Publicado: (2017)

Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS
por: Heinke, Reinhard, et al.
Publicado: (2021)

Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS
por: Heinke, Reinhard, et al.
Publicado: (2021)

Reconditioning of the Leuven Isotope Separator as a test bench for radioactive ion beam development
por: Wojtaczka, Wiktoria, et al.
Publicado: (2023)

Mass separation of 225Ac for medical applications: first proof of principle at CERN-MEDICIS
por: Heines, Michael
Publicado: (2021)

α-Zirconium(IV) Phosphate: Static Study of (225)Ac Sorption in an Acidic Environment and Its Kinetic Sorption Study Using (nat)Eu as a Model System for (225)Ac
por: Ondrák, Lukáš, et al.
Publicado: (2023)

The in vivo fate of (225)Ac daughter nuclides using polymersomes as a model carrier
por: Kruijff, R. M. de, et al.
Publicado: (2019)

Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy
por: Królicki, Leszek, et al.
Publicado: (2021)

Detailed decay spectroscopy of $^{225}$Ac and its daughters to support its use in medical applications
por: Cocolios, Thomas Elias, et al.
Publicado: (2023)

Functionalized TiO(2) nanoparticles labelled with (225)Ac for targeted alpha radionuclide therapy
por: Cędrowska, Edyta, et al.
Publicado: (2018)

[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022)

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy
por: Van de Voorde, Michiel, et al.
Publicado: (2021)

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy
por: Van de Voorde, Michiel, et al.
Publicado: (2021)

Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021)

Towards Alpha Dosimetry with Laser Ionized and Mass Separated 225Ac: Setup Development and Source Characterization
por: Van den Bergh, Viktor
Publicado: (2022)

Synthesis and Stability of Actinium-225 Endohedral Fullerenes, (225)Ac@C(60)
por: Mwakisege, Jofa Gideon, et al.
Publicado: (2020)

(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
por: Sathekge, Mike, et al.
Publicado: (2018)

Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022)

Laser resonance ionization spectroscopy on lutetium for the MEDICIS project
por: Gadelshin, V, et al.
Publicado: (2017)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

Comparison of the biodistribution of $^{225}$Ac and radiolanthanides as citrate complexes
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1990)

The application of poorly crystalline silicotitanate in production of (225)Ac
por: Fitzsimmons, Jonathan, et al.
Publicado: (2019)

Development of (225)Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
por: Robertson, Andrew Kyle Henderson, et al.
Publicado: (2018)

Estimating (225)Ac yield in thorium metal targets
por: Rahmani, M., et al.
Publicado: (2023)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

Cure of Disseminated Human Lymphoma with [(225)Ac]Ac-Ofatumumab in a Preclinical Model
por: Longtine, Mark S., et al.
Publicado: (2023)

Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Production of innovative radionuclides for medical applications at the CERN-MEDICIS facility
por: Bernerd, C, et al.
Publicado: (2023)

Measurement of the laser resonance ionization efficiency for lutetium
por: Gadelshin, Vadim Maratovich, et al.
Publicado: (2019)

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model
por: Merkx, Robin I. J., et al.
Publicado: (2022)

Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
por: Rumiantcev, Mikhail, et al.
Publicado: (2023)

New measurement of exotic decay of $^{225}$Ac by $^{14}$C emission
por: Guglielmetti, A, et al.
Publicado: (2001)

Cyclotron production of (225)Ac from an electroplated (226)Ra target
por: Nagatsu, Kotaro, et al.
Publicado: (2021)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

Ac-EAZY! Towards GMP-Compliant Module Syntheses of (225)Ac-Labeled Peptides for Clinical Application
por: Pretze, Marc, et al.
Publicado: (2021)

(225)Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings
por: Sathekge, Mike, et al.
Publicado: (2023)

mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
por: Sathekge, Mike, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m05j2vgsvkupfak2a1d7gaeki4